Cell and gene therapy CDMOs in Europe: 29 compared (2026)
29 of the 255 contract development and manufacturing organisations in A4BEE’s European census list cell and gene therapy manufacturing among their capabilities. The largest, with revenue over €1bn, are AGC Biologics, Catalent, Fujifilm Diosynth and Lonza. 6 sit between €250m and €1bn and 19 are smaller or niche.
By ownership: 8 family-owned, 9 private equity, 3 listed, 8 part of a pharma or industrial group and 1 state-owned. They are spread across 15 countries, led by the United Kingdom (6), France (3), Germany (3), Switzerland (3) and Belgium (2). 14 of the 29 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
29 companies
Cell and gene therapy CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| AGC BiologicsCopenhagen site expanded to 16,000 L single-use; broad multi-modality platform. | Copenhagen, Denmark | Part of a pharma or industrial groupAGC Inc. | Tier 1 | ~US$1.2 bn (global) | Monoclonal antibody, Microbial and protein, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy | medium |
| CatalentTaken private by Novo Holdings (US$16.5 bn, Dec 2024); global but with EU sites. | Somerset, NJ, United States | Part of a pharma or industrial groupNovo Holdings | Tier 1 | ~US$4.4 bn FY2024 (global) | Biologics and biosimilars, Cell and gene therapy, Oral solid dose, Sterile fill-finish | medium |
| Fujifilm Diosynth~US$8 bn global capex; Hillerød (DK) site runs 12 bioreactors. | Billingham, United Kingdom | Part of a pharma or industrial groupFujifilm | Tier 1 | ~US$2.0 bn (global) | Biologics and biosimilars, Monoclonal antibody, Viral vector and vaccine, Cell and gene therapy | medium |
| LonzaIntegrated Biologics grew +32.2% CER in 2025; the sector's clear scale + digital leader. | Basel, Switzerland | Listed | Tier 1 | CHF 6.5 bn (2025) | Biologics and biosimilars, Monoclonal antibody, Antibody-drug conjugate (ADC), Small-molecule API, Cell and gene therapy, Microbial and protein | high |
| ExotheraViral-vector and nucleic-acid CDMO; Univercells subsidiary. First CDMO with access to Quantoom's continuous-RNA Nfinity platform. | Jumet, Belgium | Part of a pharma or industrial groupUnivercells | Tier 2 | not disclosed | Viral vector and vaccine, mRNA and LNP, Cell and gene therapy | high |
| FinVectorcGMP viral-vector (adenoviral) gene-therapy manufacturer, FDA-approved. Now Ferring-owned and its new plant is dedicated to parent's own product — reads more captive than open CDMO. | Kuopio, Finland | Part of a pharma or industrial groupFerring | Tier 2 | not disclosed | Viral vector and vaccine, Cell and gene therapy | low |
| Minaris Advanced TherapiesCell & gene therapy CDMO (formerly Minaris Regenerative Medicine / Apceth). Merged with WuXi Advanced Therapies in 2025; Ottobrunn is the European base. | Ottobrunn, Germany | Private equityAltaris Capital Partners | Tier 2 | not disclosed | Cell and gene therapy | high |
| NorthX BiologicsBiologics CDMO built on the former Cobra Biologics Matfors site; Swedish national innovation hub for ATMPs. | Matfors, Sweden | Private equityFlerie Invest | Tier 2 | not disclosed | Microbial and protein, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy, Monoclonal antibody, Sterile fill-finish | low |
| VibalogicsSpecialist virus/viral-vector and oncolytic-virus CDMO; PE-backed. German HQ with a US site added later. | Cuxhaven, Germany | Private equityAmpersand Capital Partners | Tier 2 | not disclosed | Viral vector and vaccine, Cell and gene therapy | high |
| Viralgen Vector CoreOne of Europe's largest dedicated AAV gene-therapy vector CDMOs; founded 2017 as an AskBio subsidiary, now within Bayer. | San Sebastián, Spain | Part of a pharma or industrial groupBayer (AskBio) | Tier 2 | not disclosed | Viral vector and vaccine, Cell and gene therapy | high |
| 3PBIOVIANMerger of 3P Biopharmaceuticals (Spain) + Biovian (Finland). | Noáin, Spain | Private equityKeensight | Tier 3 | ~US$81 m | Microbial and protein, Viral vector and vaccine, Cell and gene therapy | medium |
| ABL EuropeViral-vector CDMO (adeno, lenti, AAV, pox/MVA). Acquired by Oxford Biomedica in 2024. | Lyon, France | ListedOxford Biomedica | Tier 3 | not disclosed | Viral vector and vaccine, Cell and gene therapy | high |
| BioinovaGMP contract manufacturer of ATMPs — stem-cell/MSC therapies for clinical trials. Spin-off of the Czech Academy of Sciences. | Prague, Czechia | Family-owned | Tier 3 | not disclosed | Cell and gene therapy | high |
| Cell-EasyCell-therapy CDMO (T/NK, MSCs, HSCs; autologous & allogeneic). Proprietary CellReady MSC platform. | Toulouse, France | Family-owned | Tier 3 | not disclosed | Cell and gene therapy | high |
| CellisticiPSC-based cell-therapy CDMO (launched 2022 by Ncardia). Venture-backed. | Gosselies, Belgium | Private equityNcardia | Tier 3 | not disclosed | Cell and gene therapy | medium |
| Celonic | Basel, Switzerland | Family-ownedJRS Group | Tier 3 | n/d | Monoclonal antibody, Biologics and biosimilars, Cell and gene therapy | medium |
| eXmoor PharmaIndependent full-service cell & gene therapy CDMO + CMC consultancy. | Bristol, United Kingdom | Private equityMVM Partners | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine, Biologics and biosimilars | medium |
| GenIbet BiopharmaceuticalsBiologics CDMO: microbial, cell culture, viral process dev + cGMP manufacture plus fill-finish. Made mRNA material for Moderna. | Oeiras, Portugal | Part of a pharma or industrial groupRecipharm | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, Viral vector and vaccine, Cell and gene therapy, mRNA and LNP, Sterile fill-finish | high |
| HiTech HealthFirst Irish company licensed to contract-manufacture cell & gene therapies. End-to-end ATMP CDMO with EU/UK QP release. | Galway, Ireland | Family-owned | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine, Biologics and biosimilars | high |
| Miltenyi BioindustryCDMO division of Miltenyi Biotec for lentiviral vectors and cell/gene therapies (supplied LVV for Adaptimmune TECELRA). | Bergisch Gladbach, Germany | Family-ownedMiltenyi Biotec | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine | low |
| NecstGenNon-profit cell & gene therapy CDMO and centre of excellence in a purpose-built Leiden GMP facility; genuine third-party CGT manufacturing. | Leiden, Netherlands | State-owned | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine | medium |
| Northway BiotechCEE cost-competitive biologics CDMO scaling to 5,000 L stainless steel. | Vilnius, Lithuania | Family-owned | Tier 3 | n/d | Monoclonal antibody, Microbial and protein, Biologics and biosimilars, Sterile fill-finish, Viral vector and vaccine, Cell and gene therapy | medium |
| Oxford BiomedicaLSE-listed pure-play viral-vector / cell & gene therapy CDMO (lentiviral, AAV, adenoviral). | Oxford, United Kingdom | Listed | Tier 3 | £128.8 m (FY2024) | Viral vector and vaccine, Cell and gene therapy, Biologics and biosimilars, mRNA and LNP | high |
| RoslinCTAdvanced-therapy (cell & gene) CDMO spun out of the Roslin Institute. Manufactures CASGEVY, first FDA-approved CRISPR gene therapy. | Edinburgh, United Kingdom | Private equityGHO Capital / Pioneer Group | Tier 3 | not disclosed | Cell and gene therapy | high |
| Symbiosis Pharmaceutical ServicesIndependent sterile aseptic fill-finish CDMO (clinical + commercial): mAbs, ATMPs, viral vectors, ADCs, vaccines. FDA-inspected. | Stirling, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Antibody-drug conjugate (ADC), Biologics and biosimilars, Cell and gene therapy, Small-molecule API | medium |
| ten23 healthSterile drug-product formulation & fill-finish CDMO (biologics, cell & gene therapy); absorbed swissfillon (Visp) in 2021. | Basel, Switzerland | Private equity3i Group | Tier 3 | not disclosed | Sterile fill-finish, Biologics and biosimilars, Cell and gene therapy | high |
| TouchlightCDMO making enzymatic 'doggybone DNA' (dbDNA) as template for mRNA/viral-vector/genetic medicines. First synthetic-DNA maker with MHRA GMP API cert. | London, United Kingdom | Private equity | Tier 3 | not disclosed | Cell and gene therapy, mRNA and LNP, Viral vector and vaccine | medium |
| Wellgem BiopharmaBiologics contract dev/manufacturing: mammalian + microbial cell-line/process dev, cGMP cell banking, Phase II pilot facility. Newer entrant. | Vilnius, Lithuania | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Monoclonal antibody, Microbial and protein, Viral vector and vaccine, Cell and gene therapy | medium |
| YposkesiCell & gene therapy CDMO (AAV + lentiviral vectors). Spun out of Genethon; SK pharmteco majority. | Corbeil-Essonnes, France | Part of a pharma or industrial groupSK pharmteco | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine | high |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)